Sudan Loganadane

Sudan Loganadane asked about Kymera's conviction in KT-621's opportunity in asthma, given that not all AD treatments have translated well to asthma, and requested theoretical and preclinical data supporting STAT6 degradation's potential in this indication.

Answer

CEO Nello Mainolfi expressed strong conviction in KT-621's asthma opportunity, citing dupilumab's robust activity in eosinophilic asthma via IL-4/IL-13 blockade. He explained that KT-621's STAT6 degradation mechanism mimics this blockade, as evidenced by extensive preclinical studies and early clinical data showing robust activity on biomarkers and efficacy endpoints. He specifically noted that FeNO reduction in AD patients with comorbid asthma was more robust than observed with biologics.

Sudan Loganadane asked about KT-621's opportunity in asthma, specifically what theoretical and preclinical data provide conviction, given that not all AD treatments have translated well to asthma.

Answer

Nello Mainolfi, Founder, President, and CEO, highlighted that dupilumab, which blocks IL-4 and IL-13, has demonstrated robust activity in eosinophilic asthma and other respiratory conditions. He stated that STAT6 biology, extensively shown preclinically and in early clinical development, effectively mimics IL-4 and IL-13 blockade. He referred to published preclinical asthma studies showing robust activity on both biomarkers and efficacy endpoints, and noted that the FeNO reduction observed in patients was even more robust than with biologics in asthma patients, providing strong reasons for conviction.